Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Given pounces on new FDASIA provisions for "faster" direct de novo COLON 2 application

This article was originally published in Clinica

Executive Summary

Given Imaging has seized the direct de novo pathway now available under the FDA Safety and Innovation Act (FDASIA) to apply for market approval of its PillCam COLON 2 capsule endoscopy system for visualisation of the lower gastrointestinal tract. The Yoqneam, Israel firm believes that the pathway introduced by the new guidelines (www.clinica.co.uk, 14 September 2012) may expedite the regulatory approval process “by a few months”. The objective of the COLON 2 is to “improve the standard of care for patients who are currently unable to undergo an exam, while minimising potential adverse events, and reducing the risks associated with radiation-based alternative procedures, such as CT colonography or double-contrast barium enema”.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel